DexCom, Inc. (NASDAQ:DXCM) Stock Holdings Boosted by ING Groep NV

ING Groep NV lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 132.7% in the 4th quarter, Holdings Channel reports. The fund owned 76,603 shares of the medical device company’s stock after buying an additional 43,688 shares during the period. ING Groep NV’s holdings in DexCom were worth $5,957,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of DXCM. Versant Capital Management Inc bought a new position in shares of DexCom during the fourth quarter worth about $25,000. Heck Capital Advisors LLC bought a new position in shares of DexCom during the fourth quarter worth about $38,000. RPg Family Wealth Advisory LLC bought a new position in shares of DexCom during the third quarter worth about $57,000. Covestor Ltd grew its position in shares of DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after acquiring an additional 335 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after purchasing an additional 265 shares during the period. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on DXCM. Morgan Stanley upped their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Raymond James reduced their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, Sanford C. Bernstein upped their price objective on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.06.

Insider Buying and Selling at DexCom

In other news, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares in the company, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. This represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,083 shares of company stock valued at $3,309,794. 0.30% of the stock is currently owned by corporate insiders.

DexCom Price Performance

DXCM stock opened at $88.78 on Friday. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The firm has a market capitalization of $34.69 billion, a PE ratio of 62.08, a P/E/G ratio of 2.31 and a beta of 1.14. The firm has a 50-day moving average of $83.26 and a two-hundred day moving average of $75.94.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.